Partner Therapeutics, Inc.
Privately held: no public share price · United States
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Sargramostim(Leukine) | Approved | GM-CSF receptorProtein / enzyme therapeutic | Acute Myeloid Leukemia |
Zenocutuzumab(Bizengri) | Approved | HER2; HER3 (blocks NRG1 binding to HER3)Multispecific antibody | Non-Small Cell Lung CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma Cholangiocarcinoma |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Zenocutuzumab · BizengriPhase 2Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Est. primary completion 2026-12-31 · NCT02912949 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
US, FDA · FDA · Source ↗
Financial reports
No financial reports recorded.